Weekly Recap

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

ByNeurologyLive® Staff

June 11th 2022

Neurology News Network for the week ending June 11, 2022. [WATCH TIME: 3 minutes]

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

ByNeurologyLive® Staff

May 28th 2022

Neurology News Network for the week ending May 28, 2022.

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

ByNeurologyLive® Staff

May 21st 2022

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

ByNeurologyLive® Staff

May 14th 2022

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

ByNeurologyLive® Staff

May 7th 2022

Neurology News Network for the week ending May 7, 2022. [WATCH TIME: 4 minutes]

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

ByNeurologyLive® Staff

April 30th 2022

Neurology News Network for the week ending April 30, 2022. [WATCH TIME: 4 minutes]

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

ByNeurologyLive® Staff

April 23rd 2022

Neurology News Network for the week ending April 23, 2022. [WATCH TIME: 3 minutes]

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

ByNeurologyLive® Staff

April 16th 2022

Neurology News Network for the week ending April 16, 2022 [WATCH TIME: 3 minutes]

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

ByNeurologyLive® Staff

April 9th 2022

Neurology News Network for the week ending April 9, 2022. [WATCH TIME: 4 minutes]

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

ByNeurologyLive® Staff

April 2nd 2022

Neurology News Network for the week ending April 2, 2022. [WATCH TIME: 3 minutes]

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

ByMarco Meglio

March 26th 2022

Neurology News Network for the week ending March 26, 2022. [WATCH TIME: 4 minutes]

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

ByNeurologyLive® Staff

March 19th 2022

Neurology News Network for the week ending March 19, 2022.

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

ByNeurologyLive® Staff

March 12th 2022

Neurology News Network for the week ending March 12, 2022. [WATCH TIME: 4 minutes]

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

ByNeurologyLive® Staff

February 26th 2022

Neurology News Network for the week ending February 26, 2022. [WATCH TIME: 3 minutes]

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

ByNeurologyLive® Staff

February 19th 2022

Neurology News Network for the week ending February 19, 2022. [WATCH TIME: 3 minutes]

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

ByNeurologyLive® Staff

February 12th 2022

Neurology News Network for the week ending February 12, 2022. [WATCH TIME: 3 minutes]

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

ByNeurologyLive® Staff

February 5th 2022

Neurology News Network for the week ending February 5, 2022. [WATCH TIME: 4 minutes]

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

ByNeurologyLive® Staff

January 29th 2022

Neurology News Network for the week ending January 29, 2022.

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

ByNeurologyLive® Staff

January 22nd 2022

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

ByNeurologyLive® Staff

January 15th 2022

Neurology News Network for the week ending January 15, 2022. [WATCH TIME: 4 minutes]

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

ByNeurologyLive® Staff

January 8th 2022

Neurology News Network for the week ending January 8, 2022. [WATCH TIME: 3 minutes]

Neurology News Network: Top FDA Approvals of 2021

ByNeurologyLive® Staff

January 1st 2022

Neurology News Network for the week ending January 1, 2022. [WATCH TIME: 4 minutes]

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

ByMarco Meglio

December 25th 2021

Neurology News Network for the week ending December 25, 2021.

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

ByNeurologyLive® Staff

December 18th 2021

Neurology News Network for the week ending December 18, 2021. [WATCH TIME: 3 minutes]

Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients

ByNeurologyLive® Staff

December 11th 2021

Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

ByNeurologyLive® Staff

December 4th 2021

Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

ByNeurologyLive® Staff

November 27th 2021

Neurology News Network for the week ending November 27, 2021.

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

ByNeurologyLive® Staff

November 20th 2021

Neurology News Network for the week ending November 20, 2021.

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

ByNeurologyLive® Staff

November 13th 2021

Neurology News Network for the week ending November 13, 2021.

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

ByNeurologyLive® Staff

November 6th 2021

Neurology News Network for the week ending November 6, 2021.

Weekly Recap

6-Week Natalizumab Dosing Efficacious, MS Cognitive Perceptions, Glatiramer Acetate Depot Shines in Progressive MS

AbbVie Submits NDA for ABBV-951, Periconceptional Folic Acid Supplementation Lowers Preterm Birth Risk, FDA Accepts NDA for Zavegepant

Diazepam Increased Time Between Cluster Intervals, Higher Dose Nusinersen Shows Extra Benefit, Lecanemab BLA Submitted

Ravulizumab Meets Primary End Point in NMOSD, Dosing Initiated in TRANQUILITY II Study, NIH Launches EBV Vaccine Trial

Risdiplam Shows Safety at 3-Year Period, FDA Issues CRL for AXS-07, Cognitive Tests Improve Responder Profiles in MS

Pitolisant Being Evaluated for Idiopathic Hypersomnia, FDA Approves Ravulizumab for Generalized Myasthenia Gravis, Gender Differences in MS Disease Activity

Risk Factors Identified for Posttraumatic Seizures, Acupuncture Benefits in Insomnia, Erenumab Improves Migraine in Patients Unresponsive to Prophylactics

Vutrisiran FDA Decision Extended, Gamma Sensory Stimulation Shows Benefit in Alzheimer, DBS Programming Software Greenlit

Once-Nightly Sodium Oxybate Preferred in Narcolepsy, ABBV-951 Shines in PD, Ocrelizumab Demonstrates Improved Cognitive Function in Progressive MS

Biogen Submits Protocol for Phase 4 Aducanumab Study, FDA AdComm's Board Doesn't Recommend AMX0035 Approval, Intensive SBP Increases Cerebral Blood Flow

Tobacco Smoking Increases MS Risk, Autism Risk Increased in Pediatric Stroke, Zolgensma Improves Bulbar Function

Initial Phase 4 RESPOND Results, Omaveloxolone Continues to Perform in FA, Wearable Sensors Safe for FSHD

Cladribine Shows No Increased COVID-19 Risks, Migraine Preventative Preferences, Benefits of Mobile Stroke Units

RapidAI Detects ICH With High Accuracy, Fenfluramine Plasma Levels Low, Nerivio More Effective With Behavioral Intervention

Carbidopa Levodopa Fractional Tablet Launched, Tenecteplase Shows Benefit After 24-Hour Window, Biogen Issues Response to CMS on Aducanumab

Non-Whites Underrepresented in MS DMT Trials, Stroke Risk in PD-Related Genes, Phase 2a ADv Study Initiated

Optimal Teneceplase Dosing for Elders Identified, BMI Associated With Worse Cognitive Decline, Slight Improvements in Migraine Preventive Use

CPAP Not Suggested for Elders, sNDA Accepted for Risdiplam in Presymptomatic SMA, Phase 2 Trial of GV-971 Gets Greenlight

YTX-7739 Trials Suspended, ENSURE-2 Study of IMU-838 Initiated, Behavioral Involvement of FTD in ALS

MAO-B Inhibitors Underused in PD, CMS Proposes Decision on Aducanumab Coverage, PREMIUM II Trial of gammaCore Published

Awake vs Asleep DBS Impact, Worsened MS Following DMT Discontinuation, Anticoagulation Noninferior to Avoiding it

Neurology News Network: Top FDA Approvals of 2021

Aducanumab Cost Cut, REFINE-ALS Details Announced, NMOSD Shows Brighter Spotty Lesions Than MOGAD

BXCL501 Study in Alzheimer Begins, Ublituximab BLA Accepted, Sublingual Apomorphine Shows Dominance

Perampanel Improves Comorbid Intellectual Disability, Effects of CBTip in PNES, Cenobamate's Impact in Surgically-Refractory Patients

Perampanel Improves Comorbid Epilepsy and Migraine, Masupidine to Treat Alzheimer Agitation, Fenfluramine Potential FDA-Approval in LGS

ATH-1017 Phase 2 Completes Enrollment, Heart Rate Variability as SUDEP Biomarker, Migraine Not Associated With Insomnia

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

Cladribine Tablets Show Ability to Improve or Stabilize Cognitive Function in Patients With Relapsing Multiple Sclerosis

Cladribine Maintains Efficacy, Safety Profile in Older Patients With Multiple Sclerosis

Myelin Protective Small Molecule Lucid-MS Shows Promising Early-Stage Data in Healthy Volunteers

CD40L Inhibitor Frexalimab Enters Phase 3 FREXITE Trial of Non-Relapsing Secondary Progressive Multiple Sclerosis

Using Human iPSC Models to Dissect PIRA Mechanisms in Progressive Multiple Sclerosis: Valentina Fossati, PhD